SynXT Therapeutics is developing a first-in-class therapy that selectively targets triple negative breast cancer. We overcome the severe toxicity and low response rates of standard chemotherapy by leveraging a unique vulnerability of cancer cells. Our goal is to transform TNBC treatment from palliative care into a potentially curative path.

Key Value Prepositions

Tumor-Selective

Our therapy is engineered to activate only within the high-ROS environment of tumors, precisely targeting cancer cells while sparing healthy tissue. This groundbreaking selectivity aims to eliminate the severe, debilitating side effects—like neuropathy and cardiotoxicity—that are synonymous with conventional chemotherapy.

Biomarker-Defined 

A first-in-class therapy delivering superior, targeted efficacy for the ~22,500 U.S. TNBC patients annually whose tumors carry a TP53 mutation. Our treatment is engineered to be broadly effective across all cancers while demonstrating maximized potency against this fundamental cancer driver.

Proven Preclinical Efficacy

Our compelling data shows complete tumor regression in multiple triple-negative breast cancer xenograft models, with no recurrence observed. This demonstrates a potent and durable effect that significantly outperforms the current standard of care in preclinical studies.

Novel Paradigm

We solved the 20-year translational challenge of ROS-activated prodrugs by introducing a synergistic combination that selectively boosts intratumoral ROS to therapeutic levels. This represents a fundamental shift away from toxic, non-selective chemotherapy toward a truly targeted, oxidative stress-based treatment strategy.

Top News/Updates

September 2025 – SynXT achieves a major milestone by submitting its first Phase I Small Business Technology Transfer (STTR) application to pursue federal funding for advanced research and development.

May 2025 – Dr. Taufeeque Ali and Dr. Xiaohua Peng, co-founders of SynXT, are honored with the Innovator Award from the University of Wisconsin-Milwaukee Research Foundation (UWMRF), recognizing their groundbreaking work and potential for impact.

April 2025 – SynXT is awarded an Accelerating Medical Product Development through Networked Resources (AMPDNR) grant to leverage critical resources and expertise for advancing its medical technology.

March 2025 – The company receives a Micro-Grant from the Center for Technology Commercialization (CTC) to support early-stage commercialization activities and technology assessment.

January 2025 – SynXT is officially established as a C-Corporation, marking its formal transition from a research project to a dedicated corporate entity.

December 2024 – SynXT is awarded a consultant mini-grant from the University of Wisconsin-Milwaukee Research Foundation (UWMRF) I-Corps program to support customer discovery and market validation efforts.